• Haemonetics Corp HAE.N reported quarterly adjusted earnings of $1.27​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $1.12. The mean expectation of eleven analysts for the quarter was for earnings of $1.11 per share. Wall Street expected results to range from $1.07 to $1.16 per share.

• Revenue fell 5.3% to $327.32 million from a year ago; analysts expected $311.40 million.

• Haemonetics Corp's reported EPS for the quarter was 81 cents​.

• The company reported quarterly net income of $38.68 million.

• Haemonetics Corp shares had risen by 4.1% this quarter and lost 35.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 2.7% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"

• Wall Street's median 12-month price target for Haemonetics Corp is $73.00, about 30.5% above its last closing price of $50.72

This summary was machine generated from LSEG data November 6 at 12:36 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)